title: Effective treatment with fucoidin for perinatal hypoxic-ischemic encephalopathy in rats.
abstract: Leukocyte-endothelial adhesion is a key step to initiate post-ischemic reperfusion injury in many organs. In this study, we found that the expressions of P-selectin mRNA and protein were increased in the ipsilateral hemisphere with a peak at 8 h after hypoxia-ischemia in immature brain. Such temporal profiles of P-selectin expression followed by hypoxia-ischemia are consistent with a role in the subsequent brain injury. Because fucoidin is known to inhibit P/L-selectin mediated leukocyte adhesion, we examined whether the treatment of fucoidin attenuates hypoxia-ischemia-induced neural damages. Treatment with fucoidin exhibited a substantial neuroprotective effect in a dose-dependent manner and inhibited the leukocyte adhesion significantly, as revealed by myeloperoxidase activity. These results suggest that anti-adhesion strategy may be an effective therapeutic application for the perinatal hypoxic-ischemic encephalopathy.
authors.affiliation: Brain Korea 21, Biomedical Sciences Strategic, Korea University, Seoul, South Korea.
authors.forename: C-S
authors.initials: CS
authors.lastname: Uhm
authors.forename: K-B
authors.initials: KB
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Lim
authors.forename: D-H
authors.initials: DH
authors.lastname: Pee
authors.forename: Y-H
authors.initials: YH
authors.lastname: Kim
authors.forename: H
authors.initials: H
authors.lastname: Kim
authors.forename: B-L
authors.initials: BL
authors.lastname: Eun
authors.forename: Y-C
authors.initials: YC
authors.lastname: Tockgo
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000925:Anticoagulants / Q000627:therapeutic use*; D015153:Blotting, Western / Q000379:methods; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002544:Cerebral Infarction / Q000188:drug therapy / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007839:Functional Laterality; D016179:Granulocyte Colony-Stimulating Factor; D016298:Hematopoietic Cell Growth Factors / Q000378:metabolism; D020925:Hypoxia-Ischemia, Brain / Q000188:drug therapy*; D007377:Interleukin-3; D019007:P-Selectin / Q000235:genetics / Q000378:metabolism; D011134:Polysaccharides / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D016298:Hematopoietic Cell Growth Factors; D007377:Interleukin-3; D019007:P-Selectin; D011134:Polysaccharides; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; C404145:myelopoietin; D016179:Granulocyte Colony-Stimulating Factor; C007789:fucoidan